Lixte Biotechnology Holdings, Inc. (LIXT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Lixte Biotechnology Holdings, Inc. is a drug discovery company focused on developing new treatments. It employs biomarker technology to identify crucial enzyme targets associated with serious, widespread diseases, then designs innovative compounds to act upon these targets.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $7.21, LIXT has negative trailing earnings (P/E not meaningful) and an ROE of -62.18%. Market capitalisation stands at $89M.
Balance sheet quality for LIXT: current ratio of 3.9, net cash position of $4.4M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $7.21 |
| Market Cap | $89M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.06 |
| EV / EBITDA | -30.96 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -62.18% |
| Return on Invested Capital | -42.33% |
| Return on Assets | -47.19% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 12.87 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LIXT | Lixte Biotechnology Holdings, Inc. | $89M | 4.06 | -62.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | +0.00% |
| 3 months | -5.26% |
| Year-to-date | +83.46% |
| 1 year | +28.06% |
| 3 years | +285.56% |
| 5 years | -66.47% |
52-Week Range
| 52-week High | $8.38 |
| 52-week Low | $1.28 |
| Avg Volume (90d) | 175K |
Related companies: ALLR · BCTX · CASI · CING · CLSD · ENTO · HOTH
Explore sector: Healthcare · Biotechnology
More sections of LIXT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks